GNS Healthcare Secures $23 Million Series D Funding to Expand AI-Powered Healthcare Analytics Platform

VCBeat (WeChat ID: vcbeat) learned from foreign media reports that on July 9, GNS Healthcare (GNS) completed a $23 million Series D financing round. The round was led by Cigna Ventures, with participation from Amgen Ventures, Celgene, Echo Health Ventures, Alexandria Venture Investments, as well as Gary Loveman, former CEO of Caesars and former President of the Aetna division. GNS Healthcare plans to use the funds to expand its AI-driven data analytics business.

GNS Healthcare (GNS) is a healthcare data analytics company founded in 2000 and headquartered in Cambridge, Massachusetts, USA. Led by its Chairman, CEO, and Co-founder Colin Hill, the company focuses on applying and advancing big data analytics to help healthcare providers address challenges in care delivery, treatment, and medical costs. GNS boasts a multidisciplinary team comprising physicists, actuaries, geneticists, engineers, computer scientists, and business leaders, dedicated to solving healthcare resource allocation problems for health insurers, biopharmaceutical companies, and health systems by leveraging massive and diverse data streams for precision medicine and personalized care management.

GNS partners with leading biopharmaceutical companies to accelerate and optimize their drug discovery, development, and commercialization processes. The company’s platform leverages clinical trial data and real-world data (RWD) to simulate patient treatment outcomes, enabling pharmaceutical companies to directly observe the diverse responses of patient subpopulations and determine the underlying causes of these responses. These models can also be used to simulate clinical trials and generate real-world evidence to demonstrate the efficacy of drugs in real-world settings.

GNS also collaborates with innovative health insurance companies to determine when and which pharmaceutical and care interventions should be implemented by in-network healthcare providers, enabling insurers to evaluate the effectiveness of these interventions.

Furthermore, GNS Healthcare collaborates with foundations and academic research institutions to facilitate the discovery of novel disease treatment regimens and drug targets, thereby accelerating drug development.

GNS Healthcare’s causal machine learning model, REFS (Reverse Engineering and Forward Simulation), goes beyond analyzing data correlations to infer causal relationships between variables. By transforming diverse and rich data streams, it enables the development of personalized treatment plans and care interventions, thereby significantly improving patient health outcomes and reducing total healthcare costs. The company has established learning models for more than 40 diseases across fields such as oncology, cardiovascular and metabolic disorders, neurology, and autoimmune diseases.

Cigna Ventures is a wholly-owned venture capital subsidiary of The Cigna Group, headquartered in Connecticut, USA. The company is dedicated to accelerating the growth of startups in the healthcare sector, with a primary focus on investments in digital health, as well as the retail, care, and management industries.

Amgen Ventures, established in 2004 and headquartered in San Francisco, California, USA, maintains offices in Washington State and Cambridge, Massachusetts. As the venture capital arm of Amgen, it primarily invests in early- and late-stage companies across North America, Europe, and the United Kingdom. Amgen Ventures focuses on the biotechnology sector, covering therapeutic areas such as oncology, inflammation, hematology, nephrology, metabolic disorders, neuroscience, and cardiovascular diseases. Its typical investment ranges from $2 million to $3 million, with a maximum investment of $10 million.

Celgene is a global, integrated biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory disorders. The company is currently investigating combination drug regimens for hematologic malignancies and solid tumors, with indications including multiple myeloma (MM), myelodysplastic syndromes (MDS), chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), pancreatic cancer, non-small cell lung cancer, and melanoma.

Echo Health Ventures, founded in 2016 and headquartered in Seattle, Washington, USA, maintains offices in Oregon, USA, and Durham, UK. As a private equity and venture capital firm, Echo Health Ventures is dedicated to helping build leading healthcare companies, primarily engaging in early- and late-stage investments.

Headquartered in San Francisco, California, Alexandria Venture is a strategic venture capital arm of Alexandria Real Estate Equities. The firm focuses on investing in innovative life science technology companies that develop breakthrough technologies and therapies, primarily participating in seed, early-stage, and growth-stage investments.

(Compiled by Tang Lulu)